KYMR
NASD Kymera Therapeutics, Inc.$111.52 ↑ +1.01 (+0.91%) Trading Up from the previous close of $110.51
- YTD change
- +43.32%
- vs 20-day SMA
- -3.95%
- vs 200-day SMA
- +20.31%
Price ranges
Price & Performance
+31.03 (+39.04%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 14.2% away from all-time highs of $130.05
- KYMR is up 43% since the beginning of the year
- KYMR is up 97% over the past 12 months
- KYMR is down 6% over the past 1 month
- 14% of all KYMR investors are betting against KYMR
KYMR reads neutral: price sits above one of the two key moving averages, the 12-month move is +95.2%.
- Previous minute
- +$4.52
- Last hour
- +$0.83
- Last 5 days
- -8.64%
- vs 8-day SMA
- -3.36%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
